CENTER FOR DRUG EVALUATION AND RESEARCH AND CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

APPLICATION NUMBER: 103950/0

ADMINISTRATIVE DOCUMENTS

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATIONAND RESEARCH

DATE:

November 14, 2001

FROM:

Victoria Tyson-Medlock

TO:

License Number 1080

SUBJECT:

Summary Basis of Approval

BLA:

103950/0

Manufacturer:

Amgen, Incorporated

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Drug License Name:

anakinra, Interleukin-1 receptor antagonist (IL-1Ra)

• Drug Trade Name:

Kineret

Indications and Usage

Interleukin-1 receptor antagonist (IL-1Ra), anakinra is indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs). Kineret can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents.

Dosage Form, Route of Administration and Recommended Dosage

Anakinra is supplied in a single use preservative free, 1 mL prefilled glass syringes with 27 gauge needles. Each prefilled syringe contains 0.67 mL (100mg) of anakinra. Kineret is dispensed in packs containing 7 syringes. It is also available in a 4 x 7 syringe dispending pack (28 syringes).

Basis of Approval

The basis of approval of anakinra for the treatment of rheumatoid arthritis is contained in the following appended documentation:

Review Discipline	Reviewer	Date	Location
Product-Final Drug	Ray Donnelly	11-06-01	CBER Correspondence
Clinical	Jeffrey Siegel	11-20-01	CBER Correspondence
Clin/Pharm	Martin Green	8-25-01	CBER Correspondence
Pharm/Tox	Anne Pilaro	11-13-01	CBER Correspondence
Biostatistics	Boguang Zhen	12-13-00	CBER Correspondence
BiMo	Debra Bower	10-16-00	CBER Correspondence
Facility	Reginald Neal	5-25-01	CBER Correspondence